Precigen’s (PGEN) “Buy” Rating Reaffirmed at HC Wainwright

Precigen (NASDAQ:PGEN)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $4.00. HC Wainwright’s target price would indicate a potential upside of 430.97% from the stock’s current price.

Separately, JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.00.

Precigen Trading Down 4.2 %

Shares of PGEN opened at $1.13 on Thursday. The company has a market cap of $330.94 million, a PE ratio of -2.05 and a beta of 1.65. The stock has a 50-day moving average price of $0.92 and a 200-day moving average price of $1.06. Precigen has a 12-month low of $0.65 and a 12-month high of $1.93.

Institutional Trading of Precigen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Traphagen Investment Advisors LLC purchased a new position in shares of Precigen during the third quarter valued at approximately $29,000. Stifel Financial Corp grew its stake in Precigen by 94.9% in the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 15,680 shares during the period. SG Americas Securities LLC grew its stake in Precigen by 44.2% in the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 13,823 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Precigen by 86.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 25,681 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Precigen by 56.7% in the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.